N/A N=1,480 An International Pulmonary Embolism Registry Using EKOS
Pulmonary Embolism and Thrombosis
Primary: Change in RV/LV Ratio on Echocardiogram (Matched Pairs as Available) — -22.6; -22.6 Percent change
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
N/A N=106 FlowTriever Pulmonary Embolectomy Clinical Study
Pulmonary Embolism · Acute Pulmonary Embolism · Submassive Pulmonary Embolism
Primary: Change in RV/LV Ratio — 0.38 RV/LV ratio — p=< 0.0001
Phase 3 N=350 Breath Analysis Technique to Diagnose Pulmonary Embolism
Pulmonary Embolism
Primary: Phase I: Percentage Change in the Postoperative End Tidal CO2/O2 Ratio and D-dimer Concentration Relative to the Preoperative Measurement — 0; 136 percent change
N/A N=15 Controlled Arterial Protection to Ultimately Remove Embolic Material
Aortic Valve Stenosis
Primary: Number of Participants With Procedural Success — 14 Participants
N/A N=48 Embolization in Splenic Trauma
Trauma to the Spleen
Primary: Number of Participants Who Were Enrolled Within 18 Months of Study Initiation — 23; 23 Participants
N/A N=499 Embosphere® PROstate Post Market Study
Benign Prostatic Hyperplasia · Lower Urinary Tract Symptoms
Primary: Long-term Effectiveness of Prostatic Artery Embolization (PAE) With Embosphere Microspheres as Assessed by the International Prostate Symptom Score (IPSS). — -11.1…
N/A N=101 EmboCube Gelatin Embolization to Control Bleeding or Hemorrhaging
Hemorrhage · Bleeding Hemorrhage
Primary: Number of Participants With Clinical Success: Cessation of Bleeding up to 24 Hours — 100 Participants
N/A N=115 FlowTriever for Acute Massive Pulmonary Embolism (FLAME)
PE - Pulmonary Embolism · PE - Pulmonary Thromboembolism
Primary: Composite Incidence of All-cause Mortality, Clinical Deterioration, Bailout, and Major Bleeding — 9; 39 Participants
Phase 2 N=78 Nitric Oxide to Treat Pulmonary Embolism
Pulmonary Embolism
Primary: Number of Participants With Normal Right Ventricular (RV) Function and Viability — 9; 5 Participants
N/A N=10 Selective Pulmonary-artery Intervention to Reduce Acute Right-heart tEnsion-I
Pulmonary Embolism
Primary: Change in Right Ventricle/Left Ventricle (RV/LV) Ratio — -0.4 Ratio
Phase 1 N=9 First - In - Man Study to Assess the Safety and Feasibility of The Bashir™ Endovascular Catheter for the Treatment of Acute Pulmonary Embolism
Pulmonary Embolism
Primary: Safety: Number of Participants With Major Bleeding Events — 1 Participants
N/A N=119 Evaluating the Safety and Efficacy of the Indigo® Aspiration System in Acute Pulmonary Embolism
Pulmonary Embolism
Primary: Right Ventricle/Left Ventricle (RV:LV) Ratio — 0.43 Change in RV/LV Diameter Ratio
N/A N=746 Pulmonary Embolism as a Cause of COPD Exacerbations
Pulmonary Embolism · Chronic Obstructive Pulmonary Disease
Primary: All-cause Mortality, Symptomatic Venous Thromboembolism Recurrence, or Need for Readmission. — 110; 107 Participants
Phase 4 N=581 Chemoprophylaxis Plus Early Ambulation
Pulmonary Embolism · Thoracic Surgery
Primary: Incidence of Postoperative Pulmonary Embolism (PE) in Surgical Thoracic Patients Under Currently Used PE Prevention Strategies. — 3 Participants
N/A N=1,000 FlowTriever All-Comer Registry for Patient Safety and Hemodynamics
PE - Pulmonary Embolism · PE - Pulmonary Thromboembolism
Primary: Subjects With Major Adverse Events — 24; 964 Participants
N/A N=102 Prospective Evaluation to Characterize the Real-World Performance of the EMBOVAC Aspiration Catheter
Acute Ischemic Stroke
Primary: Percentage of Participants With Successful Revascularization — 98.0 Percentage of participants
N/A N=23 Bridge Occlusion Balloon in Lead Extraction Procedure
C.Surgical Procedure; Cardiac · Cardiac Dysrhythmia · Disorder of Pacing Function
Primary: Number of Participants With Successful Balloon Occlusion of Superior Vena Cava — 18; 5 Participants
N/A N=363 Cerebral Protection in Transcatheter Aortic Valve Replacement
Severe Symptomatic Calcified Native Aortic Valve Stenosis
Primary: Reduction in Median Total New Lesion Volume in Protected Territories Between Test and Control Arms as Assessed by DW-MRI at Day 2-7 Post-procedure. — 109.1; 174 mm3
N/A N=64 The PROTEMBO C Trial
Valvular Heart Disease
Primary: Rate of Participants With MACCE Events — 3 Participants
N/A N=40 Genicular Artery Embolization for the Treatment of Knee Osteoarthritis
Knee Osteoarthritis · Degenerative Joint Disease of Knee
Primary: Number of Participants Experiencing Treatment-related Adverse Events, as a Measure of Safety — 1; 7; 2 Participants
Phase 4 N=208 Thromboaspiration in Patients With High Thrombotic Burden Undergoing Primary Percutaneous Coronary Intervention (PCI)
Primary PCI for STEMI
Primary: Rate of Complete ST-segment Elevation Resolution at 60 Minutes After the End of the Procedure — 38; 58 Participants
Phase 2 N=134 Study to Assess the Safety, Pharmacokinetics/Dynamics of DS-1040b in Subjects With Acute Submassive Pulmonary Embolism
Pulmonary Embolism · Thrombotic Disease
Primary: Number of Participants Experiencing Adjudicated Clinically Relevant Bleeding Events Following Intravenous Infusion of DS-1040b or Placebo in Addition to Standard of Care…
Phase 3 N=150 Submassive and Massive Pulmonary Embolism Treatment With Ultrasound Accelerated Thrombolysis Therapy
Pulmonary Embolism · Acute Pulmonary Embolism · Sub-massive Pulmonary Embolism
Primary: Change From Baseline in the Right Ventricle (RV) Diameter-to-Left Ventricle (LV) Diameter Ratio Within 48 +/- 6 Hours of Initiation of Therapy — 1.55; -0.42 ratio
N/A N=190 Pulmonx Endobronchial Valves Used in Treatment of Emphysema (LIBERATE Study)
Emphysema
Primary: Forced Expiratory Volume in 1-second (FEV1) — 61; 10 Participants
Phase 3 N=66 Prophylactic Topical Epinephrine to Reduce Bleeding in Transbronchial Lung Biopsies
Lung Transplant; Complications, Mechanical · Lung Transplant; Complications · Bleeding
Primary: Intra-procedural Hemorrhage Grading by the Performing Bronchoscopist — 4; 13; 11; 24 Procedures
Phase 3 N=109 tPA by Endovascular Administration for the Treatment of Submassive PE Using CDT for the Reduction of Thrombus Burden
Pulmonary Embolism
Primary: Efficacy: RV/LV Ratio Difference — 1.66; 1.10; -0.56 RV/LV Ratio
N/A N=50 FlowTriever2 Pulmonary Embolectomy Clinical Study
Pulmonary Embolism
Primary: Primary Safety Endpoint (Composite): Incidence of Adjudicated Serious Adverse Events (SAE) — 0; 50 Participants
N/A N=47 Nitrogen Bubble Detection After Simulated Dives in Divers With PFO and After PFO Closure
Patent Foramen Ovale
Primary: Arterial Nitrogen Bubbles After Surfacing — 0; 6; 0; 7 participants — p=0.02
Phase 2 N=118 Mechanical Retrieval and Recanalization of Stroke Clots Using Embolectomy
Stroke
Primary: The Modified Rankin Scale Score — 3.9; 3.4; 4.0; 4.4 units on a scale
N/A N=122 Evaluating the Safety and Efficacy of the AlphaVac Multipurpose Mechanical Aspiration (MMA) F1885 PE for Treatment of Acute Pulmonary Embolism
Pulmonary Embolism · Acute Pulmonary Embolism
Primary: Change in Right Ventricle to Left Ventricle (RV/LV) Ratio Between Baseline and 48 Hours Post-procedure Assessed by Computed Tomography Angiography (CTA) — -0.45 ratio